Please check your internet connection and try again.
# L-Ornithine L-Aspartate
## Overview
L-Ornithine L-Aspartate (LOLA) is a combination of the amino acids L-ornithine and L-aspartate. It is believed to help reduce ammonia levels in the blood.
## Primary Indications
* Treatment of hyperammonemia associated with liver disease, such as cirrhosis.
## Adult Dosing
* **Oral:** Typically 3-6 grams three times daily.
* **Intravenous (IV):** Often initiated at 5 grams twice daily, with doses up to 10 grams three times daily for severe cases. Specific IV dosing and infusion rates can vary significantly based on patient condition and local protocols.
## Pediatric Dosing
* Limited data available for pediatric use. Dosing should be individualized and guided by expert consultation or specific pediatric protocols.
## Dose Adjustments
* No dose adjustment is typically required for renal or hepatic impairment, as the drug is metabolized in the liver and its metabolites are excreted renally. However, caution is advised in severe renal impairment.
## Contraindications
* Known hypersensitivity to L-ornithine or L-aspartate.
* Severe renal failure (CrCl < 25 mL/min) due to potential accumulation of metabolites.
## Adverse Effects
* Gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain).
* Flatulence.
* Rarely, skin rash or allergic reactions.
## Key Drug Interactions
* No significant drug interactions are well-established.
## Monitoring
* Serum ammonia levels.
* Renal function.
* Liver function tests.
* Clinical signs and symptoms of hepatic encephalopathy.
## Clinical Pearls
* LOLA is often used as an adjunct therapy to manage hepatic encephalopathy.
* Oral formulations may be more effective when taken with meals.
* The IV formulation is typically used for more acute or severe hyperammonemia.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and clinical guidelines for definitive patient management.*
